GlassScriptPhysician profile
Phillip A Goldmeier
NPI 1164405437
$21,172.95
in general payments reported to CMS, 2019-2025
37 companies · $1,986 in 2025
The $1,986 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,490 · 2020: $675 · 2021: $1,203 · 2022: $12K · 2023: $1,490 · 2024: $2,551 · 2025: $1,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,829 · Consulting Fee: $1,000 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,828.81 |
| Consulting Fee | $1,000.00 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $11,275.00 | 2022-2024 | Pillcam |
| Abbvie INC. | $2,059.23 | 2019-2025 | |
| Janssen Biotech, INC. | $1,547.72 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,180.12 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $799.98 | 2021-2024 | Zeposia |
| Pfizer INC. | $643.57 | 2019-2025 | |
| Gilead Sciences, INC. | $537.10 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $379.66 | 2019-2025 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $296.62 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $247.69 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $234.56 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $221.89 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $214.19 | 2021-2024 | Linzess |
| Merck Sharp & Dohme LLC | $195.27 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $173.25 | 2021-2024 | Rebyota |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $124.08 | 2021-2023 | |
| Amgen INC. | $107.14 | 2022-2023 | Avsola, Amjevita |
| Janssen Scientific Affairs, LLC | $99.36 | 2019 | |
| Braintree Laboratories, INC. | $71.72 | 2019 | |
| Qol Medical, LLC | $71.51 | 2019-2025 | Sucraid |
| Intercept Pharmaceuticals, INC. | $67.01 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $65.66 | 2024-2025 | Zenpep |
| Ucb, INC. | $54.54 | 2019 | |
| Capsovision, INC. | $49.49 | 2024-2025 | Capsocam Plus |
| Phathom Pharmaceuticals, INC. | $49.32 | 2023-2025 | Voquezna |
| Madrigal Pharmaceuticals | $45.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $45.16 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $43.88 | 2024 | Iqirvo |
| Sandoz INC. | $42.50 | 2023 | Hyrimoz |
| Organon LLC | $39.47 | 2024-2025 | Renflexis, Hadlima |
| Daiichi Sankyo INC. | $38.73 | 2022-2023 | Injectafer |
| Welch Allyn | $34.47 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $30.23 | 2022-2023 | Andexxa |
| Shield Therapeutics INC | $28.87 | 2024 | |
| Redhill Biopharma INC. | $27.05 | 2020 | |
| Celltrion USA INC. | $20.20 | 2025 | Vegzelma |
| Cook Medical LLC | $11.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Goldmeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.